A preoperative evaluation must
Dr Joshua Steinberg's PreopEval14
If you evaluate preoperative patients you’re likely already familiar with PreOpEval and if you’re not, you should be. Created by Dr Joshua Steinberg, it’s just been updated with PreopEval14 and continues to provide high-quality, evidence-based guidelines for the preoperative evaluation of patients undergoing non-cardiac surgery and perioperative medication management. The app, based on the American College of Cardiology's (ACC) algorithm, covers surgery urgency and risk, cardiac conditions or lack of them, and a spate other clinical factors, including:
• blood-work before surgery
• common perioperative medications
• the timing of non-cardiac surgery after an M.I.
• indications for preoperative electrocardiography, chest radiography and blood tests
• patients on warfarin, aspirin, and clopidogrel
• perioperative use of B-blockers or statins
Writes the app’s creator: “This app is written and intended for practicing physicians like internists, family physicians and hospitalists; for resident physician trainees; and for medical students. In addition to being a reference, the algorithm is written to be a teaching tool by not just delivering an answer, but instead walking a physician through the evaluation process so that one learns that process along the way.”
Reviewers are enthusiastic, finding it carefully researched yet concise, highly readable and easy-to-use — a significant achievement given the complexity of the original sources which include guidelines from the aforementioned ACC, the American Heart Association (AHA), the Institute for Clinical Systems Improvement, and the American College of Chest Physicians. Indeed, the information on which the app is based is so comprehensive and clearly written that more than one reviewer has recommended it as a model for anyone engaged in building medical apps.
PreopEval14 by Dr Joshua Steinberg
Devices: iPhone only
This article was accurate when it was published. Please confirm rates and details directly with the companies in question.